Drug intelligence / Profile preview

Aleeto

Development stage: Phase 2
Lead developer: Beijing Darwin Cell Biotechnology
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Aleeto (protein polymer alitol) is an investigational recombinant protein polymer therapeutic being developed by Tsinghua University Yuquan Hospital for the treatment of mild to moderate Alzheimer's disease. The drug is designed to target pathological processes in the brain, potentially involving the inhibition or clearance of amyloid-beta aggregates. Aleeto is administered via intravenous infusion, with early clinical protocols evaluating a two-week treatment regimen. It is currently undergoing Phase 1 clinical evaluation in China to assess its safety, tolerability, and preliminary efficacy in patients with cognitive impairment.

Brand names: AleetoFosamaxBinosto
Other names: protein polymer alitolalitol

Targets

TARDBP (TAR DNA-binding protein 43)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on Aleeto.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aleeto.